E. Catalá

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment

G. Iacoboni, E. Catalá, P. Barba, 2022, Medicina Clínica (English Edition).

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

J. Briones, J. Sancho, J. Sanz, 2022, Haematologica.

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

F. Bosch, P. Abrisqueta, A. Órfão, 2021, Blood Advances.

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

B. Tazón-Vega, J. Castellví, A. Marín-Niebla, 2022, Leukemia & lymphoma.

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy

F. Bosch, P. Abrisqueta, Á. Vidal-Jordana, 2021, Annals of Hematology.

Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapy

F. Bosch, M. Tintoré, Á. Vidal-Jordana, 2022, Hematological oncology.

Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

F. Bosch, P. Abrisqueta, C. Carpio, 2021, Leukemia & lymphoma.